OrbiMed Advisors LLC Reduces Stake in Avalo Therapeutics (AVTX) to 2.1%

OrbiMed Advisors LLC filed a Schedule 13G/A on May 15, 2026, disclosing a reduced ownership stake in Avalo Therapeutics, Inc. (AVTX). As of the event date on March 31, 2026, the reporting person beneficially owns 475,165 shares of Common Stock, representing 2.1% of the company. This filing marks Amendment No. 3 and reflects a significant decrease from previous reporting, where the filer's ownership has now fallen below the 5% threshold. OrbiMed Advisors LLC, a Delaware-based investment adviser, exercises shared voting and dispositive power over these shares through a management committee consisting of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. The filing includes a certification that the securities were not acquired for the purpose of influencing or changing the control of the issuer. The reported value of the current holding is approximately $8.43 million based on recent market data.